Skip to main content
. 2026 Oct 26;17:1940896. doi: 10.3389/fimmu.2026.1940896

Figure 2.

Scientific figure with a schematic (panel A) illustrating an experimental timeline where mice receive LPS or PBS intratracheally, followed 24 hours later by MRS2578 or PBS, and lung samples collected at 48 hours. Panels B–I show bar graphs comparing groups for various cell counts and cytokine concentrations in BAL or lung, with statistical significance indicated. Each bar represents one group, individual data points are shown, and axes are clearly labeled.

Pharmacological inhibition of P2RY6 attenuates inflammatory features of LPS-induced ARDS during therapeutic treatment. Wild-type female mice received i.t. administration of LPS or PBS, followed 24 hours later by i.t. administration of MRS2578 or PBS. Mice were euthanized 24 hours after P2RY6 inhibitor administration. (A) Schematic representation of the therapeutic treatment protocol in the ARDS mouse model. (B, C) Estimated numbers of Ly6G+F4/80⁻ neutrophils and F4/80+Ly6G⁻ macrophages in BAL fluid, expressed as estimated number of cells per mouse, were quantified by flow cytometry following therapeutic P2RY6 inhibition. n indicates the number of mice analyzed. (D–H) Concentrations of pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) and chemokines (MIP-2 and KC) in BAL were measured following therapeutic treatment using an R&D Systems (I) Pulmonary vascular leakage was assessed by Evans blue–albumin extravasation. Evans blue dye (20 mg/kg) was intravenously injected via the tail vein, and dye accumulation in lung tissue was quantified spectrophotometrically. Data are presented as mean ± SEM. Statistical analysis was performed using ordinary one-way ANOVA followed by Šídák’s multiple-comparisons test, comparing each treatment group with the LPS control group (PBS/LPS). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, not significant.